Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

Prof. DING Jian graduated with his PhD degree from Kyushu University. DING Jian, Academician of Chinese Academy of Engineering, is Director of Cancer Research Center and the principal investigator at the Division of Antitumor Pharmacology of Shanghai Institute of Materia Medica. He is also the Editor-in-chief of Acta Pharmacologica Sinica and the Member of Editorial Board of Eur J Pharmacol, Cancer Biol Ther, J Ethnopharmacol, and Mol Pharmacol.

Dr. Ding’s laboratory focuses on the discovery and development of targeted agents, and in parallel on identifying biomarkers to accelerate the process of drug development and to assist the clinical use. He is one the pioneers in targeted anticancer drug discovery in China and is the co-inventor of 14 innovative drug candidates, and all of them are at clinical trials, six of them are simultaneously conducting clinical research in U.S. or Japan. More than 330 papers have been published in journals including Cell, Cancer Cell, Cell Res, Hepatology, Sig Transduct Target Ther, Nat Commun etc., with a total citation over 7600 times. Over 280 patents have been authorized or filed for application. He has been awarded 2 second degree of National Natural Science Award, the 2nd National Innovation Competition Medal, the Outstanding Science and Technology Achievement Award of the Chinese Academy of Sciences, the Tanjiazhen Life Science Achievement Award, Prize of Scientific and Technological Progress of Ho Leung Ho Lee Foundation, and more than 10 Science and Technology Progress Awards at ministerial or provincial levels.

Education

1975.11-1978.11, Jiangxi Medical University, Nanchang, China, B.S. in Pathology

1980.9-1983.9, Medical University of China, Shenyang, China, M.A. in Pathology

1986.10-1991.03, Kyushu University, Fukuoka, Japan, Ph.D. in Pathology

Work Experience

1986.10-1992.1 Kyushu University Visiting scholar

1992.2-1994.4 Shanghai Institute of Materia Medica, Postdoctoral fellow

1994.4-1995.11 Shanghai Institute of Materia Medica, Principal Investigator/ Associate Researcher

1995.12-now, Shanghai Institute of Materia Medica, Principal Investigator/Researcher

1996.3-2004.11 Shanghai Institute of Materia Medica, Deputy Director/Researcher

2004.12-2013.12 Shanghai Institute of Materia Medica, Director/Researcher

2005.1-2012.1 State key Laboratory of Drug Research, Director, Professor/Researcher

2014.06-2019.05 Shanghai Institute of Materia Medica, Director of Academic Committee

2014.01-now Dean of School of Pharmacy, Chinese Academy of Sciences

2020.08-now Director of the Oncology Center, Shanghai Institute of Materia Medica

Research Directions

Molecular targeted Anti-tumor drug development, Mechanism study & Biomarker

Grants & Research Projects

Achievements

Prof. DING Jian is a high-achieving pharmacologist; he’s made extraordinary contributions to the research and development of China’s new drugs.

Prof. DING Jian is a renowned Chinese cancer pharmacologist and Academician of the Chinese Academy of Engineering. He is a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and was Director of the Shanghai Institute of Materia Medica, CAS (2004-2013). He has been awarded many prizes and awards of great significance, such as the 2nd prize of the National Natural Science Award (2 times), 2nd prize of the National Science and Technology Progress Award, Medal from the 2nd National Innovation and Pioneer Award, Chinese Academy of Sciences Outstanding Science and Technology Achievement Award, etc.

The new drug candidates against cancer developed by Prof. Ding and his team have constructed a development and research channel for new anti-cancer drugs, which is internationally competitive. At this stage, there are 14 new drug candidates, of which he is one of the principal inventors and which have independent intellectual property rights, and 6 of which are in clinical research in U.S, and a number of other new drug candidates are undergoing systematic pre-clinical research review. More than 280 invention patents at home and abroad have been authorized or filed for application., and over ten new drugs have completed translation or transfer, which has produced tremendous economic and societal benefits.

Prof. DING Jian concentrated on key scientific problem research of anti-cancer drugs, leading his team to elucidating new mechanisms of anti-cancer drugs and to discovering new biomarkers. Ding’s team presented a systematic explanation to pharmacological mechanisms of new anti-cancer drug candidates, uncovered structural basis and action mechanism of several targeted drugs, discovered the efficacy monitoring markers for serial molecular targeted drugs, and contributed over 330 SCI papers in journals such as Cell, Cancer Cell, Cell Res, Hepatology, Sig Transduct Target Ther ,Nat Commun, Clin Cancer Res, and Cancer Res, with citations of over 7600 times.

morefold

Social Titles

1.2006.12-now, Acta Pharmacologica Sinica, Editor-in-chief;

2.2007.01-now, Cancer Biology & Therapy, Editorial board member;

3.2007.01-now, European Journal of Pharmacology, Editorial board member;

4.2007.01-now, Journal of Ethno pharmacology, Editorial board member;

5.2012.01-now, Molecular Pharmacology, Editorial board member.

6.2017.05-now, Vice Chairman of Chinese Pharmaceutical Association;

7.2012.07-now, Vice Chairman of the Chinese Pharmacological Society;

8.2017.04-now, Chairman of Shanghai Pudong New Area Science Association

9.2019.11-2024.11, Dean of Intelligent Innovation Medicine Research Institute of Zhejiang University

morefold

Awards & Honors

1.2020, the Second National Innovation Competition Award (Medal)

2.2017, First Prize of Shanghai Pharmaceutical Technology (2/6)

3.2016, Outstanding Scientific and Technological Achievement Award of Chinese Academy of Sciences

4.2016, Tan Jiazhen Life Science Achievement Award

5.2015, Advanced Science and Technology Worker of Chinese Academy of Sciences

6.2013, National Natural Science Award

7.2012, National outstanding science and technology workers

8.2009, National Natural Science Award, 2rd prize

9.2008, Prize of Scientific and Technological Progress of Ho Leung Ho Lee Foundation

10.2007, 2010 National Natural Science Award (Shanghai)

11.2006, Wu Jieping Medical-Paul Janssen Pharmaceutical Research Prize

12.2005, Top ten scientific and technological elites (Shanghai)

13.2004, 2005 Excellent Supervisor of Chinese Academy of Sciences

14.2003, National Science &Technology Award, 2rd prize

15.2003, Shanghai Science & Technology Award

16.2001, Fourth International Debio-CCRF Award, 1st Prize

morefold

Pubilcations

Full Publication List

Selected Publications

1.Huang X# , Yan J#, Zhang M# , Wang Y#, Chen Y, Fu X, Wei R, Zheng X， Liu Zh, Zhang X; Yang H，Hao B, Shen Y, Su Y, Cong X, Huang M, Tan M*, Ding J*, Geng M*.Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-aberrant Solid Tumors, Cell, 2018;175(1):186-199.

2.Zeng H#, Qu J#, Jin N#, Xu J, Lin C, Yang X, He X, Tang S, Lan X, Yang X, Chen Z, Huang M*, Ding J*, Geng M*.Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylases inhibitors in breast cancer. Cancer Cell, 2016;30(3):459-73.

3.Lian Q#, Xu J#, Yan S, Huang M*, Ding H, Sun X, Ding J*, Sun B* and Geng M*. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res. 2017;27(6):784-800.

4.Zhang T#, Qu R#, Chan Sh#, Lai M, Tong L, Feng F, Chen H, Song T, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Shen Y, Sun Y, Chen Y, Geng M, Ding K*, Ding J*, Xie H*.Discovery of a Novel Third-Generation EGFR Inhibitor and Identification of a Potential Combination Strategy to Overcome Resistance. Mol Cancer. 2020;19(1):90.

5.Wang X#, Zhang M, Ping F, Liu H, Sun J, Wang Y, Shen A, Ding J*, Geng M*. Identification and therapeutic intervention of coactivated anaplastic lymphoma kinase, fibroblast growth factor receptor 2, and ephrin type‐A receptor 5 kinases in hepatocellular carcinoma. Hepatology. 2019;69(2):573-586.

6.Yue X#, Ai J#, Xu Y#, Chen Y#, Huang M, Yang X, Hu B, Zhang H, He Ch, Yang X, Tang W, Peng X, Dong L, Wang H, Fan J*, Ding J*, Geng M*. Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. Hepatology.2017;65(6):1948-1962.

7.Xie Q, Chi Sh, Fang Y, Sun Y, Meng L, Ding J *, Chen Y*. PI3Kα inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma. Sig Transduct Target Ther. 2021;6(1):130.

8.Chen Y#, Wang Y#, Zhang J, Su Y, Shen Y, Jiang D, Hou Y , Geng M*, and Ding J*. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin . Nature Commun. 2017; 8(1):27.

9.Dai X#, Yan J#, Fu X, Pan Q, Sun D, Xu Y, Wang J, Nie L, Tong L, Shen A, Zheng M, Huang M, Tan M, Liu H, Huang X*, Ding J*, Geng M*. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clin Cancer Res. 2017;23(20):6267-6278.

10.Liu H#, Ai J#, Shen A, Chen Y, Wang X, Peng X, Chen H, Shen Y, Huang M*, Ding J*, Geng M*.c-Myc alteration determines the therapeutic response to FGFR inhibitors. Clin Cancer Res. 2017; 23(4):974-984.

morefold